schizophrenia

But as Bhat’s company, Reviva Pharmaceuticals Holdings Inc. (NASDAQ: RVPH), pushes an experimental schizophrenia drug toward topline data this month from a late-stage clinical trial, the founder and …

Oct 16 2023

Uncategorized

Atlanta police asking for the public’s help locating missing senior with schizophrenia

by Clinical Editor

No Comments

Officials say Ferrer Euclides was last seen earlier today before he left his home in Southwest Atlanta unannounced.

Oct 16 2023

Uncategorized

‘Integrating the stuff that scares you’: life with schizophrenia

by Clinical Editor

No Comments

The range of diagnoses that make up schizophrenia spectrum disorders are hard to define and tricky to diagnose. An author, an artist and a blogger tell their own stories about...

Oct 16 2023

Uncategorized

Karuna plans to more than double its workforce if schizophrenia drug is approved

by Clinical Editor

No Comments

Karuna, which began clinical trials of a first-of-its-kind schizophrenia drug called KarXT in 2016, has grown rapidly from about 20 employees in 2020 to more than 300 today.

Oct 16 2023

Uncategorized

Looking Back on Living With Untreated Schizophrenia

by Clinical Editor

No Comments

My anosognosia story Prior to my diagnosis, I did not realize schizophrenia had dramatically altered my sense of reality. Because of this, I spent four years homeless. I remember when...

Oct 15 2023

Uncategorized

Brain inflammation in young children may contribute to autism, schizophrenia – UPI News

by Clinical Editor

No Comments

Brain inflammation in young children may contribute to autism, schizophrenia UPI News

Oct 15 2023

Uncategorized

Atlanta police asking for the public’s help locating missing senior with schizophrenia

by Clinical Editor

No Comments

Officials say Ferrer Euclides was last seen earlier today before he left his home in Southwest Atlanta unannounced.

Oct 15 2023

Uncategorized

Schizophrenia drug developer eyes late-stage clinical trial data this month

by Clinical Editor

No Comments

At times he had to take detours. But as Bhat’s company, Reviva Pharmaceuticals Holdings Inc. (NASDAQ: RVPH), pushes an experimental schizophrenia drug toward topline data this month from a late-stage...